03 Février 2021

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+


Biology / Medical



98 % of the human population is chronically infected by EBV. We propose an innovative platform for engineering
immunogenic bi-modular fusion proteins comprising a binding moiety and an EBV antigen to redirect an EBV preexisting
immune response towards a select cellular target. The aim is to develop efficient therapies triggering immune
mechanisms such as Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-mediated Cytotoxicity
(ADCC) and Antibody- Dependent Phagocytosis (ADP) to combat pathogens or treat pathologies such as cancer.

Applications :

  • Treatment of cancers (such as
  • B-cell lymphomas)
    Treatment of infectious diseases
    (such as malaria)

Competitive advantages :

  • Applicable for 98 % of the population.
  • Easy to produce as compared to current therapies such as
    monoclonal antibodies.
  • Triggering of multiple immune effectors due to the recruitment of
    polyclonal antibodies.
  • Allow efficacy improvement of current therapeutic antibodies.
  • Versatile platform allowing large scale screening of binding moieties.
  • Multiple applications (treatment of a large panel of diseases).

Keywords : Epstein-Barr Virus - Therapeutic molecular engineering - Antibody
fragments - Nanobodies - Immune effectors - Cellular cytotoxicity /
complement activation

Download the offer Download the offer